- Home
- SBFM vs TOVX Comparison
SBFM vs TOVX Comparison
Compare SBFM & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- TOVX
- Stock Information
- Founded
- SBFM 2006
- TOVX 2001
- Country
- SBFM United States
- TOVX United States
- Employees
- SBFM N/A
- TOVX N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- TOVX Health Care
- Exchange
- SBFM Nasdaq
- TOVX Nasdaq
- Market Cap
- SBFM 4.6M
- TOVX 3.8M
- IPO Year
- SBFM N/A
- TOVX 2006
- Fundamental
- Price
- SBFM $1.51
- TOVX $0.47
- Analyst Decision
- SBFM Strong Buy
- TOVX Hold
- Analyst Count
- SBFM 1
- TOVX 1
- Target Price
- SBFM $15.00
- TOVX N/A
- AVG Volume (30 Days)
- SBFM 104.9K
- TOVX 1.8M
- Earning Date
- SBFM 05-15-2025
- TOVX 05-14-2025
- Dividend Yield
- SBFM N/A
- TOVX N/A
- EPS Growth
- SBFM N/A
- TOVX N/A
- EPS
- SBFM N/A
- TOVX N/A
- Revenue
- SBFM $36,234,578.00
- TOVX N/A
- Revenue This Year
- SBFM $192.48
- TOVX N/A
- Revenue Next Year
- SBFM N/A
- TOVX N/A
- P/E Ratio
- SBFM N/A
- TOVX N/A
- Revenue Growth
- SBFM 35.51
- TOVX N/A
- 52 Week Low
- SBFM $1.17
- TOVX $0.40
- 52 Week High
- SBFM $11.39
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- SBFM 54.20
- TOVX 29.91
- Support Level
- SBFM $1.37
- TOVX $0.43
- Resistance Level
- SBFM $1.56
- TOVX $0.54
- Average True Range (ATR)
- SBFM 0.08
- TOVX 0.05
- MACD
- SBFM 0.02
- TOVX 0.03
- Stochastic Oscillator
- SBFM 73.68
- TOVX 41.18
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.